抗生素对免疫检查点抑制剂治疗原发性癌症疗效的影响☆

Q2 Medicine Liver Research Pub Date : 2022-09-01 DOI:10.1016/j.livres.2022.05.004

Jia-Ren Wang , Rui-Ning Li , Chao-Yi Huang , Chang Hong , Qi-Mei Li , Lin Zeng , Jing-Zhe He , Cheng-Yi Hu , Hao Cui , Li Liu , Lu-Shan Xiao

{"title":"抗生素对免疫检查点抑制剂治疗原发性癌症疗效的影响☆","authors":"Jia-Ren Wang , Rui-Ning Li , Chao-Yi Huang , Chang Hong , Qi-Mei Li , Lin Zeng , Jing-Zhe He , Cheng-Yi Hu , Hao Cui , Li Liu , Lu-Shan Xiao","doi":"10.1016/j.livres.2022.05.004","DOIUrl":null,"url":null,"abstract":"<div><h3>Background and aim</h3><p>Immune checkpoint inhibitors (ICIs) are widely used in the treatment of liver cancer. However, the interaction with other drugs may change the efficacy of ICIs. Few studies investigated the effects of antibiotics (ATBs) on the efficacy of immunotherapy and the survival of patients with primary liver cancer receiving immunotherapy. This study aimed to explore the impact of ATBs on the efficacy of immunotherapy in patients with primary liver cancer.</p></div><div><h3>Methods</h3><p>In total, 215 patients with primary liver cancer who received ICIs from June 2018 to October 2020 were included for retrospective analysis. The progression-free survival (PFS), disease control rate (DCR), and overall survival (OS) were compared between patients treated with and without ATBs within 30 days before and after immunotherapy.</p></div><div><h3>Results</h3><p>No significant differences in PFS (<em>P</em> = 0.376) and OS (<em>P</em> = 0.121) were found between patients treated with and without ATBs. Univariate and multivariate analyses showed that using ATBs was not associated with PFS, DCR, and OS.</p></div><div><h3>Conclusion</h3><p>The use of ATBs within 30 days before and after immunotherapy in patients with primary liver cancer had no adverse effects on PFS, DCR, and OS.</p></div>","PeriodicalId":36741,"journal":{"name":"Liver Research","volume":"6 3","pages":"Pages 175-180"},"PeriodicalIF":0.0000,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2542568422000228/pdfft?md5=d885f83d21f0312736ae12d0b3bf3841&pid=1-s2.0-S2542568422000228-main.pdf","citationCount":"2","resultStr":"{\"title\":\"Impact of antibiotics on the efficacy of immune checkpoint inhibitors in the treatment of primary liver cancer\",\"authors\":\"Jia-Ren Wang , Rui-Ning Li , Chao-Yi Huang , Chang Hong , Qi-Mei Li , Lin Zeng , Jing-Zhe He , Cheng-Yi Hu , Hao Cui , Li Liu , Lu-Shan Xiao\",\"doi\":\"10.1016/j.livres.2022.05.004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background and aim</h3><p>Immune checkpoint inhibitors (ICIs) are widely used in the treatment of liver cancer. However, the interaction with other drugs may change the efficacy of ICIs. Few studies investigated the effects of antibiotics (ATBs) on the efficacy of immunotherapy and the survival of patients with primary liver cancer receiving immunotherapy. This study aimed to explore the impact of ATBs on the efficacy of immunotherapy in patients with primary liver cancer.</p></div><div><h3>Methods</h3><p>In total, 215 patients with primary liver cancer who received ICIs from June 2018 to October 2020 were included for retrospective analysis. The progression-free survival (PFS), disease control rate (DCR), and overall survival (OS) were compared between patients treated with and without ATBs within 30 days before and after immunotherapy.</p></div><div><h3>Results</h3><p>No significant differences in PFS (<em>P</em> = 0.376) and OS (<em>P</em> = 0.121) were found between patients treated with and without ATBs. Univariate and multivariate analyses showed that using ATBs was not associated with PFS, DCR, and OS.</p></div><div><h3>Conclusion</h3><p>The use of ATBs within 30 days before and after immunotherapy in patients with primary liver cancer had no adverse effects on PFS, DCR, and OS.</p></div>\",\"PeriodicalId\":36741,\"journal\":{\"name\":\"Liver Research\",\"volume\":\"6 3\",\"pages\":\"Pages 175-180\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2542568422000228/pdfft?md5=d885f83d21f0312736ae12d0b3bf3841&pid=1-s2.0-S2542568422000228-main.pdf\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Liver Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2542568422000228\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Liver Research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2542568422000228","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 2

摘要

背景与目的免疫检查点抑制剂(ICIs)广泛应用于肝癌的治疗。然而，与其他药物的相互作用可能会改变ICIs的疗效。很少有研究调查抗生素(ATBs)对免疫治疗的疗效和原发性肝癌患者接受免疫治疗的生存的影响。本研究旨在探讨ATBs对原发性肝癌患者免疫治疗疗效的影响。方法回顾性分析2018年6月至2020年10月期间接受ICIs治疗的215例原发性肝癌患者。比较免疫治疗前后30天内接受和不接受ATBs治疗的患者的无进展生存期(PFS)、疾病控制率(DCR)和总生存期(OS)。结果两组患者的PFS (P = 0.376)和OS (P = 0.121)差异无统计学意义。单因素和多因素分析显示，使用ATBs与PFS、DCR和OS无关。结论原发性肝癌患者免疫治疗前后30天内使用ATBs对PFS、DCR和OS无不良影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Impact of antibiotics on the efficacy of immune checkpoint inhibitors in the treatment of primary liver cancer

Background and aim

Immune checkpoint inhibitors (ICIs) are widely used in the treatment of liver cancer. However, the interaction with other drugs may change the efficacy of ICIs. Few studies investigated the effects of antibiotics (ATBs) on the efficacy of immunotherapy and the survival of patients with primary liver cancer receiving immunotherapy. This study aimed to explore the impact of ATBs on the efficacy of immunotherapy in patients with primary liver cancer.

Methods

In total, 215 patients with primary liver cancer who received ICIs from June 2018 to October 2020 were included for retrospective analysis. The progression-free survival (PFS), disease control rate (DCR), and overall survival (OS) were compared between patients treated with and without ATBs within 30 days before and after immunotherapy.

Results

No significant differences in PFS (P = 0.376) and OS (P = 0.121) were found between patients treated with and without ATBs. Univariate and multivariate analyses showed that using ATBs was not associated with PFS, DCR, and OS.